vs
Ginkgo Bioworks Holdings, Inc.（DNA）与摩托罗拉系统（ISSC）财务数据对比。点击上方公司名可切换其他公司
Ginkgo Bioworks Holdings, Inc.的季度营收约是摩托罗拉系统的1.5倍（$33.4M vs $21.8M），摩托罗拉系统同比增速更快（36.6% vs -23.8%），摩托罗拉系统自由现金流更多（$7.0M vs $-47.7M），过去两年摩托罗拉系统的营收复合增速更高（42.5% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
摩托罗拉系统是一家美国科技企业，专注于研发供应安全防护相关产品与服务，总部位于伊利诺伊州芝加哥。公司主营关键通信、视频安防与指挥中心技术，相关产品与服务面向公共安全机构及各类企业。公司于2011年从原摩托罗拉拆分而来，是原摩托罗拉的合法继承主体，原摩托罗拉手机业务拆分后成为摩托罗拉移动。
DNA vs ISSC — 直观对比
营收规模更大
DNA
是对方的1.5倍
$21.8M
营收增速更快
ISSC
高出60.4%
-23.8%
自由现金流更多
ISSC
多$54.7M
$-47.7M
两年增速更快
ISSC
近两年复合增速
-6.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $21.8M |
| 净利润 | — | $4.1M |
| 毛利率 | — | 54.5% |
| 营业利润率 | -211.9% | 28.9% |
| 净利率 | — | 18.6% |
| 营收同比 | -23.8% | 36.6% |
| 净利润同比 | — | 451.4% |
| 每股收益（稀释后） | $-1.41 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DNAISSC
| Q4 25 | $33.4M | $21.8M | ||
| Q3 25 | $38.8M | $22.2M | ||
| Q2 25 | $49.6M | $24.1M | ||
| Q1 25 | $48.3M | $21.9M | ||
| Q4 24 | $43.8M | $16.0M | ||
| Q3 24 | $89.0M | $15.4M | ||
| Q2 24 | $56.2M | $11.8M | ||
| Q1 24 | $37.9M | $10.7M |
净利润DNAISSC
| Q4 25 | — | $4.1M | ||
| Q3 25 | $-80.8M | $7.1M | ||
| Q2 25 | $-60.3M | $2.4M | ||
| Q1 25 | $-91.0M | $5.3M | ||
| Q4 24 | — | $736.2K | ||
| Q3 24 | $-56.4M | $3.2M | ||
| Q2 24 | $-217.2M | $1.6M | ||
| Q1 24 | $-165.9M | $1.2M |
毛利率DNAISSC
| Q4 25 | — | 54.5% | ||
| Q3 25 | — | 63.2% | ||
| Q2 25 | — | 35.5% | ||
| Q1 25 | — | 51.4% | ||
| Q4 24 | — | 41.4% | ||
| Q3 24 | — | 55.4% | ||
| Q2 24 | — | 53.4% | ||
| Q1 24 | — | 52.0% |
营业利润率DNAISSC
| Q4 25 | -211.9% | 28.9% | ||
| Q3 25 | -231.8% | 37.0% | ||
| Q2 25 | -132.1% | 14.6% | ||
| Q1 25 | -184.1% | 31.8% | ||
| Q4 24 | -236.3% | 8.4% | ||
| Q3 24 | -62.0% | 28.4% | ||
| Q2 24 | -396.7% | 17.3% | ||
| Q1 24 | -469.1% | 15.3% |
净利率DNAISSC
| Q4 25 | — | 18.6% | ||
| Q3 25 | -207.9% | 32.0% | ||
| Q2 25 | -121.6% | 10.1% | ||
| Q1 25 | -188.2% | 24.3% | ||
| Q4 24 | — | 4.6% | ||
| Q3 24 | -63.3% | 20.7% | ||
| Q2 24 | -386.4% | 13.2% | ||
| Q1 24 | -437.3% | 11.3% |
每股收益（稀释后）DNAISSC
| Q4 25 | $-1.41 | $0.22 | ||
| Q3 25 | $-1.45 | $0.40 | ||
| Q2 25 | $-1.10 | $0.14 | ||
| Q1 25 | $-1.68 | $0.30 | ||
| Q4 24 | $-1.91 | $0.04 | ||
| Q3 24 | $-1.08 | $0.18 | ||
| Q2 24 | $-4.23 | $0.09 | ||
| Q1 24 | $-3.32 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $8.3M |
| 总债务越低越好 | — | $23.8M |
| 股东权益账面价值 | $508.6M | $68.7M |
| 总资产 | $1.1B | $109.9M |
| 负债/权益比越低杠杆越低 | — | 0.35× |
8季度趋势，按日历期对齐
现金及短期投资DNAISSC
| Q4 25 | $422.6M | $8.3M | ||
| Q3 25 | $495.5M | $2.7M | ||
| Q2 25 | $559.4M | $601.8K | ||
| Q1 25 | $325.3M | $1.2M | ||
| Q4 24 | $561.6M | $604.6K | ||
| Q3 24 | $616.2M | $539.0K | ||
| Q2 24 | $730.4M | $521.0K | ||
| Q1 24 | $840.4M | $574.1K |
总债务DNAISSC
| Q4 25 | — | $23.8M | ||
| Q3 25 | — | $24.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DNAISSC
| Q4 25 | $508.6M | $68.7M | ||
| Q3 25 | $559.8M | $64.6M | ||
| Q2 25 | $613.0M | $56.8M | ||
| Q1 25 | $647.4M | $53.5M | ||
| Q4 24 | $716.1M | $47.8M | ||
| Q3 24 | $797.9M | $46.6M | ||
| Q2 24 | $833.1M | $43.2M | ||
| Q1 24 | $987.3M | $41.4M |
总资产DNAISSC
| Q4 25 | $1.1B | $109.9M | ||
| Q3 25 | $1.2B | $103.4M | ||
| Q2 25 | $1.2B | $91.8M | ||
| Q1 25 | $1.3B | $89.9M | ||
| Q4 24 | $1.4B | $81.3M | ||
| Q3 24 | $1.5B | $82.4M | ||
| Q2 24 | $1.6B | $59.8M | ||
| Q1 24 | $1.6B | $57.6M |
负债/权益比DNAISSC
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $7.0M |
| 自由现金流率自由现金流/营收 | -142.8% | 32.3% |
| 资本支出强度资本支出/营收 | 0.0% | 5.1% |
| 现金转化率经营现金流/净利润 | — | 2.01× |
| 过去12个月自由现金流最近4个季度 | — | $12.3M |
8季度趋势，按日历期对齐
经营现金流DNAISSC
| Q4 25 | $-47.7M | $8.2M | ||
| Q3 25 | $-31.6M | $3.0M | ||
| Q2 25 | $-40.3M | $7.2M | ||
| Q1 25 | $-51.5M | $1.3M | ||
| Q4 24 | $-42.4M | $1.8M | ||
| Q3 24 | $-103.5M | $445.3K | ||
| Q2 24 | $-84.4M | $934.1K | ||
| Q1 24 | $-89.3M | $201.1K |
自由现金流DNAISSC
| Q4 25 | $-47.7M | $7.0M | ||
| Q3 25 | — | $2.0M | ||
| Q2 25 | $-40.3M | $3.5M | ||
| Q1 25 | $-59.1M | $-267.7K | ||
| Q4 24 | $-56.1M | $1.6M | ||
| Q3 24 | $-118.6M | $299.5K | ||
| Q2 24 | $-111.4M | $730.8K | ||
| Q1 24 | $-96.0M | $75.4K |
自由现金流率DNAISSC
| Q4 25 | -142.8% | 32.3% | ||
| Q3 25 | — | 8.8% | ||
| Q2 25 | -81.2% | 14.6% | ||
| Q1 25 | -122.4% | -1.2% | ||
| Q4 24 | -128.0% | 9.9% | ||
| Q3 24 | -133.2% | 1.9% | ||
| Q2 24 | -198.2% | 6.2% | ||
| Q1 24 | -252.9% | 0.7% |
资本支出强度DNAISSC
| Q4 25 | 0.0% | 5.1% | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | 0.1% | 15.3% | ||
| Q1 25 | 15.8% | 7.1% | ||
| Q4 24 | 31.3% | 1.6% | ||
| Q3 24 | 16.9% | 0.9% | ||
| Q2 24 | 48.1% | 1.7% | ||
| Q1 24 | 17.7% | 1.2% |
现金转化率DNAISSC
| Q4 25 | — | 2.01× | ||
| Q3 25 | — | 0.42× | ||
| Q2 25 | — | 2.95× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 2.50× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 0.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
ISSC
| Products | $13.6M | 62% |
| Services | $8.2M | 38% |
